<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881240</url>
  </required_header>
  <id_info>
    <org_study_id>MEMCAR19</org_study_id>
    <nct_id>NCT04881240</nct_id>
  </id_info>
  <brief_title>Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia</brief_title>
  <official_title>A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel&#xD;
      CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific&#xD;
      CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old&#xD;
      with relapsed and/ or refractory CD19-positive leukemia.&#xD;
&#xD;
      Primary Objective&#xD;
&#xD;
      To determine the maximum tolerated dose (MTD) and characterize the safety profile and&#xD;
      dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells&#xD;
      in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and/or&#xD;
      refractory CD19-positive leukemia.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells.&#xD;
&#xD;
        -  To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with&#xD;
           allogeneic CD19-CAR.CD45RA-negative T-cells.&#xD;
&#xD;
      Exploratory Objectives&#xD;
&#xD;
        -  To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative&#xD;
           T-cells.&#xD;
&#xD;
        -  To characterize the cytokine profile in the peripheral blood and CSF after treatment&#xD;
           with allogeneic CD19-CAR.CD45RA-negative T-cells.&#xD;
&#xD;
        -  To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus&#xD;
           exhaustion-associated epigenetic programs.&#xD;
&#xD;
        -  To determine the clonal structure and endogenous repertoire of allogeneic&#xD;
           CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response&#xD;
           profiles.&#xD;
&#xD;
        -  To characterize incidence and mechanisms of relapse post-therapy with allogeneic&#xD;
           CD19-CAR.CD45RA-negative T-cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I dose escalation study using a 3+3 study design. Two groups of patients will&#xD;
      be evaluated in this study: group A - patients have received a prior stem cell transplant&#xD;
      from their CAR T-cell donor; group B - patients have not received a prior stem cell&#xD;
      transplant from their CAR T-cell donor. There will be up to 30 participants per group and a&#xD;
      donor/ family member for each patient.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of allogeneic, CD19-CAR.CD45RA-negative cells</measure>
    <time_frame>4 weeks after CAR T-cell infusion</time_frame>
    <description>This phase I study includes dose escalation/de-escalation based on dose limiting toxicity (DLT) assessment to determine the maximum tolerated dose (MTD) of allogeneic, CD19-CAR.CD45RA-negative cells.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Lymphoblastic Leukemia, in Relapse</condition>
  <condition>Acute Lymphoblastic Leukemia, Refractory</condition>
  <condition>Pediatric ALL</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-CAR(Mem) T-cells</intervention_name>
    <description>Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS</intervention_name>
    <description>A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Donors: Apheresis and Manufacturing&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  At least single haplotype matched (≥ 3/6) family member&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  For females of childbearing age:&#xD;
&#xD;
          -  Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days&#xD;
             prior to enrollment AND Not lactating with intent to breastfeed&#xD;
&#xD;
        Regarding donation eligibility, is identified as either:&#xD;
&#xD;
          1. Completed the process of donor eligibility determination as outlined in 21 CFR 1271&#xD;
             and agency guidance; OR&#xD;
&#xD;
          2. Does not meet 21 CFR 1271 eligibility requirements but has a declaration of urgent&#xD;
             medical need completed by the principal investigator or physician sub-investigator per&#xD;
             21 CFR 1271.&#xD;
&#xD;
        Identified recipient with relapsed and/or refractory CD19-positive leukemia who is not&#xD;
        suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:&#xD;
&#xD;
          1. Relapsed and/or refractory disease despite prior treatment with autologous CD19-CAR&#xD;
             T-cell therapy&#xD;
&#xD;
          2. History of prior autologous leukapheresis failure&#xD;
&#xD;
          3. History of prior autologous CAR T-cell manufacturing failure&#xD;
&#xD;
          4. Unable to undergo autologous leukapheresis in the opinion of the study PI (s):&#xD;
             examples may include - patient small size/low weight, inadequate T-cell counts,&#xD;
             rapidly progressive leukemia, clinical status not amenable to apheresis Inclusion&#xD;
             Criteria: Treatment&#xD;
&#xD;
               -  Age ≤ 21 years old&#xD;
&#xD;
               -  Not suitable to receive autologous CD19-CAR T-cell therapy as defined in section&#xD;
                  3.1.6&#xD;
&#xD;
               -  Relapsed and/or refractory CD19-positive leukemia*: *CD19-positivity confirmed&#xD;
                  within 2 months and after receipt of any CD19-directed therapy&#xD;
&#xD;
        Refractory disease (defined as any of the following):&#xD;
&#xD;
        1. Primary refractory disease despite at least 2 cycles of an intensive chemotherapy&#xD;
        regimen designed to induce remission 2. Refractory disease despite salvage therapy&#xD;
&#xD;
        Relapsed disease (defined as any of the following):&#xD;
&#xD;
          1. 2nd or greater relapse&#xD;
&#xD;
          2. Any relapse after allogeneic hematopoietic cell transplantation (HCT)&#xD;
&#xD;
          3. 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse&#xD;
             therapy, but is found to be ineligible and/or unsuitable for HCT&#xD;
&#xD;
        Inclusion Criteria:Patient cohorts:&#xD;
&#xD;
          -  Cohort A: patient has previously received a HCT from the selected CAR T- cell donor&#xD;
&#xD;
          -  Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell&#xD;
             donor.&#xD;
&#xD;
          -  Detectable medullary CD19-positive leukemia&#xD;
&#xD;
          -  Estimated life expectancy of ≥ 8 weeks&#xD;
&#xD;
          -  Karnofsky or Lansky performance score ≥ 50 (Appendix A)&#xD;
&#xD;
          -  No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic&#xD;
             symptoms&#xD;
&#xD;
        If history of allogeneic HCT (regardless of donor type), prior to planned CAR T- cell&#xD;
        infusion, must meet the following criteria:&#xD;
&#xD;
          1. ≥ 3 months from HCT&#xD;
&#xD;
          2. have recovered from prior HCT therapy&#xD;
&#xD;
          3. have no evidence of active GVHD within prior 2 months&#xD;
&#xD;
          4. have not received a donor lymphocyte infusion (DLI) within the 28 days prior to&#xD;
             planned CAR T-cell infusion • Adequate cardiac function: left ventricular ejection&#xD;
             fraction ≥ 40% or shortening fraction ≥ 25%&#xD;
&#xD;
             • EKG without evidence of clinically significant arrhythmia&#xD;
&#xD;
             • Adequate renal function: creatinine clearance or radioisotope GFR&#xD;
&#xD;
             ≥ 50 ml/min/1.73m2 (GFR ≥ 40 ml/min/1.73m2 if &lt; 2 years of age)&#xD;
&#xD;
             • Adequate pulmonary function: forced vital capacity (FVC) ≥ 50% of predicted value;&#xD;
             or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function&#xD;
             testing&#xD;
&#xD;
             • Total bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with&#xD;
             Gilbert's syndrome&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the&#xD;
                  upper limit of normal for age&#xD;
&#xD;
               -  No history of HIV infection&#xD;
&#xD;
               -  No evidence of severe, uncontrolled bacterial, viral or fungal infection&#xD;
&#xD;
               -  Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities&#xD;
                  from prior therapy&#xD;
&#xD;
             For females of childbearing age:&#xD;
&#xD;
        1. Not pregnant with negative serum or urine pregnancy test ≤ 7 days prior to enrollment&#xD;
        AND Not lactating with intent to breastfeed&#xD;
&#xD;
          -  If sexually active, agreement to use birth control until 6 months after CAR T-cell&#xD;
             infusion&#xD;
&#xD;
          -  No history of hypersensitivity reactions to murine protein-containing products&#xD;
&#xD;
          -  Not receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of&#xD;
             methylprednisolone ≤ 7 days prior to CAR T-cell infusion&#xD;
&#xD;
          -  Not receiving systemic therapy ≤ 14 days prior to CAR T-cell infusion, which will&#xD;
             interfere with the activity of the CAR T-cell product in vivo (in the opinion of the&#xD;
             study PI(s))&#xD;
&#xD;
          -  Not receiving intrathecal chemotherapy ≤ 7 days prior to CAR T-cell infusion&#xD;
&#xD;
          -  Agreement to participate in long-term follow-up on protocol NCT00695279&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee C. Talleur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Gottschalk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aimee C. Talleur, MD</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee C. Talleur, MD</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Aimee C. Talleur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Gottschalk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

